GSK rises Monday, outperforms market
Shares of GSK PLC GSK advanced 1.56% to £14.66 Monday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.77% to 8,767.80. GSK PLC ...
CFRA cuts GlaxoSmithKline stock price target to $40, maintains hold
CFRA analyst Wan Nurhayati revised the price target for GlaxoSmithKline (NYSE:GSK) shares, reducing it to $40.00 from the ...
GSK Stock Jumps on Long-Term Outlook Boost, $2.5B Share Buyback Plan
Key Takeaways GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and ...
Barclays Keeps Their Hold Rating on GlaxoSmithKline (GSK)
In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target ...
GSK launches $2.5 billion buyback, lifts sales target after stellar fourth quarter
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 Billion Stock Buyback, Raises Long-Term Annual Sales Forecast To Over $50 Billion
GSK Plc (NYSE:GSK) reported fourth-quarter sales of $10.40 billion (8.12 billion Sterling Pounds), up 1% year-over-year and ...
GSK falls Friday, underperforms market
GSK PLC GSK shares slid 2.47% to £14.43 Friday, on what proved to be an all-around dismal trading session for the stock ...
GSK Reported Strong Earnings, So I Reiterate My Strong Buy
GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...
Why GSK Stock Is Surging Today
GSK generated earnings per share of 23.2 pence last quarter, versus analysts’ average estimate of 20 pence. Last quarter, its ...
GSK shares surge around 6% as drugmaker raises sales target and boosts dividends
GSK shares surge as the drugmaker raises its 2031 sales target to over £40bn, boosts dividends, and announces a £2bn share ...
Deutsche Bank Keeps Their Hold Rating on GlaxoSmithKline (GSK)
Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...